https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51044 Wed 16 Aug 2023 11:19:37 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46698 Wed 13 Mar 2024 08:07:19 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48997 35 cigarettes/day. Lung cancer risk was lower with quitting at any age but remained higher than never-smokers for quitters aged >25y. By age 80y, an estimated 48.3% of current-smokers (41.1% never-smokers) will develop cancer, and 14% will develop lung cancer, including 7.7% currently smoking 1-5 cigarettes/day and 26.4% for >35 cigarettes/day (1.0% never-smokers). Cancer risk for Australian smokers is significant, even for 'light' smokers. These contemporary estimates underpin the need for continued investment in strategies to prevent smoking uptake and facilitate cessation, which remain key to reducing cancer morbidity and mortality worldwide.]]> Wed 03 May 2023 12:03:16 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50708 Wed 02 Aug 2023 15:00:51 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49325 Tue 14 Nov 2023 14:39:43 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33342 Thu 28 Oct 2021 13:04:32 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43348 Thu 15 Sep 2022 15:25:41 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30828 50% or PPV >65% for either cancer type and no combination of indicators increased both the sensitivity and PPV above that achieved using the hospital cancer diagnosis data. All specificities were close to 100%; 95% confidence intervals for sensitivity and PPV were generally +/−2%. Conclusions: In NSW, identifying new cases of colorectal and lung cancer from administrative health datasets, such as hospital records, is a feasible alternative when cancer registry data are not available. However, the strengths and limitations of the different data sources should be borne in mind.]]> Thu 13 Jan 2022 10:30:22 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:35066 Thu 13 Jan 2022 10:28:51 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52851 30%. For each group, an age–period– cohort model or generalised linear model with cigarette smoking exposure as a covariate was selected based on the model fit statistics and validation using observed data. The smoking-attributable fraction (SAF) was calculated for each smoking-related cancer using Australian smoking prevalence data and published relative risks. Results: Despite the decreasing mortality rates projected for the period 2015–2019 to 2040–2044 for both men and women, the overall number of smoking-related cancer deaths is estimated to increase by 28.7% for men and 35.8% for women: from 138 707 (77 839 men and 60 868 women) in 2015–2019 to 182 819 (100 153 men and 82 666 women) in 2040–2044. Over the period 2020–2044, there will be 254 583 cancer deaths (173 943 men and 80 640 women) directly attributable to smoking, with lung, larynx, oesophagus and oral (comprising lip, oral cavity and pharynx) cancers having the largest SAFs. Interpretation: Cigarette smoking will cause over 250 000 cancer deaths in Australia from 2020 to 2044. Continued efforts in tobacco control remain a public health priority, even in countries where smoking prevalence has substantially declined.]]> Mon 30 Oct 2023 09:54:19 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51422 Mon 04 Sep 2023 14:57:22 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40089 p<0.0001), smoking (p<0.0001) and unknown stage (p = 0.002). There was no evidence of differences by year of diagnosis or sex (both p>0.50). For 465 cases diagnosed 2014–2015, 29% had subsidised molecular testing for targeted therapy/immunotherapy and 4% had subsidised targeted therapies. Conclusions: Lung cancer healthcare costs are strongly associated with survival-related factors. Costs appeared stable over the period 2006–2013. This study provides a framework for evaluating the health/economic impact of introducing lung cancer screening and other interventions in Australia.]]> Fri 15 Jul 2022 10:04:25 AEST ]]>